Results of the first external quality assessment scheme (EQA) for isolation and analysis of circulating tumour DNA (ctDNA)

Clinical Chemistry and Laboratory Medicine

Volumn 56, Issue 2, 2018, Pages 220-228

  Haselmann, Verena ^a   Ahmad Nejad, Parviz ^b   Geilenkeuser, Wolf J ^c   Duda, Angelika ^d   Gabor, Merle ^d   Eichner, Romy ^d   Patton, Simon ^d   Neumaier, Michael ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF WITTEN HERDECKE   (Germany)

^c Reference Institute for Bioanalytics   (Germany)

^d ST MARY S HOSPITAL   (United Kingdom)

Author keywords

circulating DNA; external quality assessment scheme; liquid biopsy; liquid profiling; plasma

Indexed keywords

B RAF KINASE; CIRCULATING TUMOR DNA; EDETIC ACID; GENOMIC DNA; K RAS PROTEIN;

ARTICLE; BLOOD SAMPLING; DNA DETERMINATION; DNA EXTRACTION; DNA ISOLATION; EXTERNAL QUALITY ASSESSMENT SCHEME; GENE FREQUENCY; GENOTYPE; HUMAN; MOLECULAR GENETICS; PLASMA VOLUME; PRIORITY JOURNAL; QUALITY CONTROL; SANGER SEQUENCING; STORAGE TEMPERATURE; CHEMICAL ANALYSIS; GENOTYPING TECHNIQUE; ISOLATION AND PURIFICATION; LIQUID BIOPSY; PROCEDURES; SPECIMEN HANDLING; STANDARDS; WORKFLOW;

CHEMISTRY TECHNIQUES, ANALYTICAL; CIRCULATING TUMOR DNA; GENOTYPING TECHNIQUES; HUMANS; LIQUID BIOPSY; PLASMA VOLUME; SPECIMEN HANDLING; WORKFLOW;

EID: 85032498559     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm-2017-0283     Document Type: Article

References (39)

1. Bidard FC, Weigelt B, Reis-Filho JS. Going with the flow: from circulating tumor cells to DNA. Sci Transl Med 2013;5:207ps14.
2. Fleischhacker M, Schmidt B. Circulating nucleic acids (CNAs) and cancer-a survey. Biochim Biophys Acta 2007;1775:181-232.
3. Diehl F, Li M, Dressman D, He Y, Shen D, Szabo S, et al. Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci USA 2005;102:16368-73.
4. Diehl F, Schmidt K, Choti MA, Romans K, Goodman S, Li M, et al. Circulating mutant DNA to assess tumor dynamics. Nat Med 2008;14:985-90.
5. Snyder MW, Kircher M, Hill AJ, Daza RM, Shendure J. Cell-free DNA comprises an in vivo nucleosome footprint that informs its tissues-of-origin. Cell 2016;164:57-68.
6. Jahr S, Hentze H, Englisch S, Hardt D, Fackelmayer FO, Hesch RD, et al. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res 2001;61:1659-65.
7. Schwarzenbach H, Hoon DS, Pantel K. Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer 2011;11:426-37.
8. Dawson SJ, Tsui DW, Murtaza M, Biggs H, Rueda OM, Chin SF, et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med 2013;368:1199-209.
9. Taniguchi K, Uchida J, Nishino K, Kumagai T, Okuyama T, Okami J, et al. Quantitative detection of EGFR mutations in circulating tumor DNA derived from lung adenocarcinomas. Clin Cancer Res 2011;17:7808-15.
10. Benesova L, Belsanova B, Suchanek S, Kopeckova M, Minarikova P, Lipska L, et al. Mutation-based detection and monitoring of cell-free tumor DNA in peripheral blood of cancer patients. Anal Biochem 2013;433:227-34.
11. Diaz LA Jr, Bardelli A. Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol 2014;32:579-86.
12. Girotti MR, Gremel G, Lee R, Galvani E, Rothwell D, Viros A, et al. Application of sequencing, liquid biopsies, and patient-derived xenografts for personalized medicine in melanoma. Cancer Discov 2016;6:286-99.
13. Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet 2015;386:444-51.
14. Ascierto PA, McArthur GA, Dreno B, Atkinson V, Liszkay G, Di Giacomo AM, et al. Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncol 2016;17:1248-60.
15. Ohhara Y, Fukuda N, Takeuchi S, Honma R, Shimizu Y, Kinoshita I, et al. Role of targeted therapy in metastatic colorectal cancer. World J Gastrointest Oncol 2016;8:642-55.
16. Tan WL, Jain A, Takano A, Newell EW, Iyer NG, Lim WT, et al. Novel therapeutic targets on the horizon for lung cancer. Lancet Oncol 2016;17:e347-62.
17. Overman MJ, Modak J, Kopetz S, Murthy R, Yao JC, Hicks ME, et al. Use of research biopsies in clinical trials: are risks and benefits adequately discussed? J Clin Oncol 2013;31:17-22.
18. Krishnamurthy N, Spencer E, Torkamani A, Nicholson L. Liquid biopsies for cancer: coming to a patient near you. J Clin Med 2017;6:3.
19. Miller WG, Jones GR, Horowitz GL, Weykamp C. Proficiency testing/ external quality assessment: current challenges and future directions. Clin Chem 2011;57:1670-80.
20. Neumaier M, Braun A, Gessner R, Funke H. Experiences with external quality assessment (EQA) in molecular diagnostics in clinical laboratories in Germany. Working Group of the German Societies for Clinical Chemistry (DGKC) and Laboratory Medicine (DGLM). Clin Chem Lab Med 2000;38:161-3.
21. Rago C, Huso DL, Diehl F, Karim B, Liu G, Papadopoulos N, et al. Serial assessment of human tumor burdens in mice by the analysis of circulating DNA. Cancer Res 2007;67:9364-70.
22. Diehl F, Li M, He Y, Kinzler KW, Vogelstein B, Dressman D. BEAMing: single-molecule PCR on microparticles in water-in-oil emulsions. Nat Methods 2006;3:551-9.
23. Saiki RK, Bugawan TL, Horn GT, Mullis KB, Erlich HA. Analysis of enzymatically amplified beta-globin and HLA-DQ alpha DNA with allele-specific oligonucleotide probes. Nature 1986;324:163-6.
24. Li J, Makrigiorgos GM. COLD-PCR: a new platform for highly improved mutation detection in cancer and genetic testing. Biochem Soc Trans 2009;37(Pt 2):427-32.
25. Sykes PJ, Neoh SH, Brisco MJ, Hughes E, Condon J, Morley AA. Quantitation of targets for PCR by use of limiting dilution. Biotechniques 1992;13:444-9.
26. Diaz LA Jr, Williams RT, Wu J, Kinde I, Hecht JR, Berlin J, et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 2012;486:537-40.
27. Little S. Amplification-refractory mutation system (ARMS) analysis of point mutations. Curr Protoc Hum Genet 2001;Chapter 9:Unit 9. 8.
28. Saiki RK, Walsh PS, Levenson CH, Erlich HA. Genetic analysis of amplified DNA with immobilized sequence-specific oligonucleotide probes. Proc Natl Acad Sci USA 1989;86:6230-4.
29. O'Sullivan MV, Zhou F, Sintchenko V, Kong F, Gilbert GL. Multiplex PCR and reverse line blot hybridization assay (mPCR/RLB). J Vis Exp 2011;54:2781.
30. Vos P, Hogers R, Bleeker M, Reijans M, van de Lee T, Hornes M, et al. AFLP: a new technique for DNA fingerprinting. Nucleic Acids Res 1995;23:4407-14.
31. Kuppuswamy MN, Hoffmann JW, Kasper CK, Spitzer SG, Groce SL, Bajaj SP. Single nucleotide primer extension to detect genetic diseases: experimental application to hemophilia B (factor IX) and cystic fibrosis genes. Proc Natl Acad Sci USA 1991;88:1143-7.
32. Molecular in vitro diagnostic examinations-Specifications for pre-examination processes for venous whole blood-Part 3: Isolated circulating cell free DNA from plasma. PD CEN/TS 16835-3:2015.
33. Malentacchi F, Pazzagli M, Simi L, Orlando C, Wyrich R, Hartmann CC, et al. SPIDIA-DNA: an External Quality Assessment for the pre-analytical phase of blood samples used for DNAbased analyses. Clin Chim Acta 2013;424:274-86.
34. El Messaoudi S, Rolet F, Mouliere F, Thierry AR. Circulating cell free DNA: preanalytical considerations. Clin Chim Acta 2013;424:222-30.
35. Devonshire AS, Whale AS, Gutteridge A, Jones G, Cowen S, Foy CA, et al. Towards standardisation of cell-free DNA measurement in plasma: controls for extraction efficiency, fragment size bias and quantification. Anal Bioanal Chem 2014;406:6499-512.
36. Chiminqgi M, Moutereau S, Pernet P, Conti M, Barbu V, Lemant J, et al. Specific real-time PCR vs. fluorescent dyes for serum free DNA quantification. Clin Chem Lab Med 2007;45:993-5.
37. Haselmann V, Geilenkeuser WJ, Helfert S, Eichner R, Hetjens S, Neumaier M, et al. Thirteen years of an international external quality assessment scheme for genotyping: results and recommendations. Clin Chem 2016;62:1084-95.
38. Berwouts S, Fanning K, Morris MA, Barton DE, Dequeker E. Quality assurance practices in Europe: a survey of molecular genetic testing laboratories. Eur J Hum Genet 2012;20:1118-26.
39. Dequeker E, Ramsden S, Grody WW, Stenzel TT, Barton DE. Quality control in molecular genetic testing. Nat Rev Genet 2001;2:717-23.